Compare VVOS & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VVOS | BGLC |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | United States | Malaysia |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7M | 4.9M |
| IPO Year | 2020 | 2019 |
| Metric | VVOS | BGLC |
|---|---|---|
| Price | $0.50 | $2.61 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $2.75 | N/A |
| AVG Volume (30 Days) | ★ 3.6M | 59.6K |
| Earning Date | 04-15-2026 | 04-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 6.76 | ★ 45.78 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $17,443,000.00 | $7,424,911.00 |
| Revenue This Year | $69.66 | N/A |
| Revenue Next Year | $48.38 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 16.05 | N/A |
| 52 Week Low | $0.45 | $1.07 |
| 52 Week High | $7.40 | $15.19 |
| Indicator | VVOS | BGLC |
|---|---|---|
| Relative Strength Index (RSI) | 33.38 | 67.94 |
| Support Level | N/A | $2.06 |
| Resistance Level | $0.76 | $2.73 |
| Average True Range (ATR) | 0.14 | 0.31 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 5.49 | 94.48 |
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.
BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.